CDSCO panel nod to Biological E to conduct Phase II trial of vaccine for 6- 8 weeks-old infants

Reviewing the Phase I clinical trial report, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the vaccine maker Biological E to conduct a Phase II clinical trial of Diphtheria, Tetanus, Pertussis (Whole cell), Hepatitis B (rDNA), inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) for 6- 8 weeks-old infants.

This came after the vaccine maker Biological E presented its proposal for the conduct of a Phase II clinical trial in 6- 8 weeks-old infants along with a Phase I clinical trial report.

For the full story, check out the link given below:

Biological E Gets CDSCO Panel Nod To Study Vaccine For 6- 8 Weeks Old Infants